Login to Your Account

Guilford’s sNDA For Gliadel Wafer Turned Down By FDA

By Kim Coghill

Thursday, March 21, 2002
A difference in opinion apparently prompted the FDA to issue Guilford Pharmaceuticals Inc. a non-approvable letter rejecting a supplemental new drug application for use of the Gliadel Wafer in patients with newly diagnosed malignant glioma. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription